Result Update 3QFY2013

Ranbaxy

For 4QCY2012 Ranbaxy Labs posted numbers above expectations on the topline front, while it reported lower-than-expected numbers on the profit front. On the sales front, the company reported a 28.8% decline to end the period at `2,671cr vs our expectation of `2,525cr. The main disappointment came on the OPM front which came in at 3.4% vs our expectation of 9.3%. In addition to this, contractual expenses along with the forex losses amounted to an  obligation of `506cr and `281cr respectively. This lead the company to post an adj. net loss of around  `154cr vs an expected net profit of  `274cr. Source: AngelBroking

Vesuvius India

For 4QCY2012, Vesuvius India (VIL) reported better-than-expected results. Its topline grew slightly by 3.5% yoy to `154cr, and 10.6% higher than our expectation of `139cr. For the full year CY2012, revenue grew by a marginal 3.8% yoy to `564cr. EBITDA margin expanded by 298bp yoy to 19.3% for the quarter from 16.3% in 4QCY2011 mainly due to reduction in other expenses. Consequently, the net profit for the quarter grew by 33% yoy from `13cr to `18cr in 4QCY2012.  Source: AngelBroking